EOFY Sale · Save up to $750 off your legals · Ends 30 June

Claim offer
Selected cases

Federal Court of Australia · [2026] FCA 657

Cannatrek scheme approval

A Federal Court scheme approval case about Cannatrek, a TGA investigation update, shareholder voting and late disclosure in a regulated...

Federal Court of Australia29 May 2026

Plain-English explainers, not legal advice. Check the linked official source before you rely on a specific section, and get advice for your situation.

Get legal help

Start here

Quick read

  • Shareholder votes do not erase late disclosure issues.
  • A Federal Court scheme approval case about Cannatrek, a TGA investigation update, shareholder voting and late disclosure in a regulated transaction.

Use this to check

  • Scheme approval depends on court scrutiny as well as shareholder voting thresholds.
  • Regulator investigations should be monitored throughout the transaction timetable.
  • Post-meeting developments can matter if they would be material to members.

Decision snapshot

  1. 1

    What happened

    • Cannatrek sought approval of a scheme of arrangement under which Little Green Pharma would acquire Cannatrek shares.
    • Cannatrek shareholders approved the scheme at a meeting on 10 April 2026, with 98.44 percent of votes cast in favour and 96.15 percent of shareholders present and voting in favour.
    • The scheme booklet had disclosed a Therapeutic Goods Administration investigation.
    • After the scheme meeting, Cannatrek received correspondence indicating an in-principle settlement with the TGA involving a civil penalty range between $2 million and $8 million.
  2. 2

    What the court had to decide

    • The Federal Court had to decide whether to approve the Cannatrek scheme under section 411(4)(b) of the Corporations Act after shareholders approved it and after new information emerged about an in-principle TGA settlement and potential civil penalty range.
  3. 3

    What the court decided

    • The Court approved the scheme under section 411(4)(b).
    • It was satisfied the statutory majorities had been met, ASIC had not opposed approval, and the later TGA penalty-range information would not have changed the shareholder vote in a way that prevented the scheme being approved.

Practical impact

Practical read

  • Shareholder votes do not erase late disclosure issues.
  • If a regulated risk changes during a transaction, boards should update the market, tell members clearly and keep evidence about whether the new information would affect the vote.

Useful next steps

  • Scheme approval depends on court scrutiny as well as shareholder voting thresholds.
  • Regulator investigations should be monitored throughout the transaction timetable.
  • Post-meeting developments can matter if they would be material to members.
  • A strong shareholder vote can be relevant, but it is not a substitute for disclosure analysis.
  • Boards should document how late transaction developments are assessed and escalated.

Practical read

Cannatrek is a corporate transaction case with a practical disclosure lesson. The shareholders had already voted strongly in favour of the scheme, but something material happened after the meeting: the TGA investigation moved to a point where an in-principle penalty range was identified. The Court then had to decide whether the scheme should still be approved.

The Court did not treat the shareholder vote as the end of the story. It considered whether the statutory voting thresholds had been met, whether the scheme remained fair and reasonable, whether ASIC had objected, and whether the new TGA information was likely to have changed the outcome if shareholders had known it before voting. The size of the vote mattered, but so did the nature of the new information and the evidence about its effect.

For founders and boards, the business lesson is to treat regulated issues as live during a sale process. If a regulator investigation, licence issue, product approval, penalty range or enforcement risk changes after documents go out, do not assume the old disclosure is enough. Update the transaction team, consider whether members or investors need more information, and keep a written record of why the decision is made.

Checks to run

Key points

  • Track regulator investigations, licences and enforcement correspondence during any sale process.
  • Update scheme, investor or buyer disclosures when material information changes.
  • Keep voting results, proxy records and member communications ready for the second court hearing.
  • Record why late information would or would not affect a reasonable shareholder's vote.
  • Coordinate board, ASIC, expert and court-timetable steps before transaction deadlines tighten.

Key takeaways

  • Scheme approval depends on court scrutiny as well as shareholder voting thresholds.
  • Regulator investigations should be monitored throughout the transaction timetable.
  • Post-meeting developments can matter if they would be material to members.
  • A strong shareholder vote can be relevant, but it is not a substitute for disclosure analysis.
  • Boards should document how late transaction developments are assessed and escalated.

Related topics

How Sprintlaw can help